Biotechnology is part of our work in Life Sciences.
Over our more than 50 years in practice, Finnegan has worked with biotech pioneers to develop and execute successful intellectual property strategies, including patenting ground-breaking advancements, enforcing patents in litigation, and defending against claims of infringement or ownership by others. We successfully represented Eli Lilly and Company in a lawsuit involving the first marketed product produced by biotechnology—human insulin—and have provided counseling or litigation services in a range of biotechnologies, such as automated DNA sequencing, the cloning of Dolly the sheep, noninvasive methods for detecting fetal aneuploidy, and platform antibody design.
Strong IP protection has been essential to advancing the biotech industry and remains key to its continued growth. As an IP law firm comprised of scientists and biotech engineers, Finnegan is structured to stay abreast of rapid advancements in science and changing legal issues in this fast-paced, multidisciplinary industry.
As our biotechnology clients make exciting breakthroughs in ways we have yet to imagine, we help by:
We work with clients advancing discoveries in established as well as emerging areas, including:
Finnegan represents BrainCo, a developer of brain-machine interface (BMI) wearables that combine electroencephalography (EEG) signal processing with artificial intelligence (AI) and machine learning (ML) to enable users to control electronic devices using brain signals. The firm works with BrainCo to develop and implement its intellectual property strategy, including drafting and prosecuting utility and design patent applications, in support of the company’s efforts to build a robust patent portfolio covering innovations and designs related to BMI technologies used in toys, smart home appliances, and robotic devices.
Representing Sarepta in defensive patent litigation involving Elevidys®, a one-time gene therapy for the treatment of a neuromuscular disease known as Duchenne muscular dystrophy (DMD) and in parallel offensive inter partes reviews (IPRs).
1:24-cv-00882, D. Del., Judge Andrews
2:23-cv-00094, 2:23-cv-02364, D.N.J., Judges Cecchi, Padin, Wettre
Representing plaintiff Pioneer in a district court patent infringement litigation involving methods for producing doubled haploid maize plants.
1:22-cv-01280, D. Del.
N22C-07-168, Delaware Superior Court, Complex Commercial Litigation Division
Representing plaintiff Corteva Agriscience in a district court patent infringement litigation involving transgenic plants and plant cells that produce enzymes conferring herbicide resistance.
1:22-cv-01046, D. Del., Judge Williams
European IP Blog
UPC Central Division Revokes Patent Covering Covid-19 Treatment Remdesivir
8 June 2026
Conference
19th Annual Forum on Pharma & Biotech Patent Litigation in Europe
May 19-20, 2026
Amsterdam
Press Release
London-Based Life Sciences Litigator Jin Ooi Bolsters Finnegan’s Global IP Litigation Capabilities
June 8, 2026
Award/Ranking
Finnegan Partner Antje Brambrink Shortlisted for Women in Business Law EMEA Award
May 13, 2026
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.